A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
Conditions: Prostate Cancer; Castration-resistant Prostate Cancer Interventions: Drug: SHR3680; Drug: SHR2554 Sponsor: Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials